Please login to the form below

Not currently logged in
Email:
Password:

Mochida and Wyeth in novel vanilloid pain tie-up

Mochida licenses a portfolio of transient receptor potential vanilloid sub type 1 (TRPV1) receptor antagonists for use as a potential novel treatment for pain to Wyeth Pharmaceuticals

Mochida Pharmaceutical has licensed a portfolio of transient receptor potential vanilloid sub type 1 (TRPV1) receptor antagonists for use as a potential novel treatment for pain to Wyeth Pharmaceuticals.

Per the Agreement, Wyeth wins an exclusive worldwide license to develop, manufacture, use and sell pharmaceutical products containing Mochida's TRPV1 antagonists. Mochida will receive an upfront payment and potential development milestone payments, as well as royalties on sales by Wyeth.

Mochida retains an option to co-develop and co-market in Japan with Wyeth.

TRPV1 is a receptor and ion channel, which is stimulated by various stimuli including capsaicin, an ingredient derived from chilli peppers.

A number of other large pharmaceutical companies are also researching TRPV1 receptors for use in reducing nociception from inflammatory and neuropathic pain models in rats. In humans, drugs acting at TRPV1 receptors could potentially be used to treat neuropathic pain associated with multiple sclerosis, chemotherapy, or amputation, as well as pain associated with the inflammatory response of damaged tissue, such as in osteoarthritis. Existing painkillers sometimes cause gastrointestinal disorders or renal disorders, which limits their use.

14th January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics